Progressive Familial Intrahepatic Cholestasis

Gastroenterology
2
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Ipsen
IpsenChina - Tianjin
2 programs
1
A4250Phase 31 trial
OdevixibatN/A1 trial
Active Trials
NCT04483531Approved For Marketing
NCT03659916Completed116Est. Dec 2025
Mirum Pharmaceuticals
Mirum PharmaceuticalsFOSTER CITY, CA
1 program
1
MaralixibatPhase 21 trial
Active Trials
NCT04729751Completed27Est. Dec 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
IpsenA4250
Mirum PharmaceuticalsMaralixibat

Clinical Trials (3)

Total enrollment: 143 patients across 3 trials

NCT03659916IpsenA4250

Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC

Start: Sep 2018Est. completion: Dec 2025116 patients
Phase 3Completed
NCT04729751Mirum PharmaceuticalsMaralixibat

A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).

Start: Sep 2021Est. completion: Dec 202427 patients
Phase 2Completed
NCT04483531IpsenOdevixibat

Odevixibat for the Treatment of Progressive Familial Intrahepatic Cholestasis

N/AApproved For Marketing

Related Jobs in Gastroenterology

Specialty Representative, Gastroenterology – Minneapolis, Minnesota

AbbVie
Remote
11h ago

Head of Drug Product Development

Ironwood Pharmaceuticals
Boston, Massachusetts, United States
12h ago
$246K - $287K/yr

Regulatory Affairs Associate

Ferring Pharmaceuticals
Istanbul, Turkey
Yesterday

Key Account Director, Diagnostics and Research

Tempus
Remote
Yesterday
$150K - $200K/yr

QA Operation Platform Lead

Johnson & Johnson
Yokneam, Haifa District, Israel
Yesterday

Value Architecture & Engineering Lead

Johnson & Johnson
Titusville, New Jersey, United States of America
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space

Related Indications

Hepatic Impairment(79)Gastroesophageal Reflux Disease(37)Irritable Bowel Syndrome(29)Gastroesophageal Reflux(27)Liver Transplantation(24)Celiac Disease(23)Hepatic Insufficiency(22)Liver Cirrhosis(22)Gastroesophageal Reflux Disease (GERD)(14)Hepatic Encephalopathy(12)